Key Highlights
● Bausch Health reported adjusted earnings of $1.77 a share.
● That beat estimates by $0.50 a share.
● The company raised its full-year outlook.
● Bausch Health holds a majority stake in Bausch + Lomb.
Bausch Health (NYSE:BHC) soared after the bell after the drugmaker reported quarterly earnings well ahead of expectations and raised its outlook for 2026. The company posted adjusted earnings of $1.77 a share, beating estimates by $0.50, and raised its full-year outlook, according to an evening earnings roundup.
A beat of $0.50 a share is a wide margin for a company of Bausch Health's size, and pairing it with a higher forecast gave investors two reasons to cheer in extended trading.
A Beat and a Raise
The full details of the revised guidance were not available in the reports reviewed. After-hours moves can be volatile and may not hold when regular trading resumes, but a raised outlook signals that management expects business conditions to remain supportive for the rest of the year.
Bausch Health is a Canadian-headquartered pharmaceutical company with a portfolio spanning gastroenterology, dermatology, neurology and other areas, with Xifaxan, an antibiotic used for certain gastrointestinal conditions, among its best-known products.
A Family Affair
The company also holds a majority stake in Bausch + Lomb, the eye-care business it spun off through an initial public offering, a stake long central to how investors value Bausch Health, particularly given its heavy debt load.
The same day, Bausch + Lomb also soared after raising its own full-year revenue and profit forecasts, making for a strong day across both Bausch companies.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...